Trials / Not Yet Recruiting
Not Yet RecruitingNCT07490613
A Phase I Study of SHR-3836 in Patients With Multiple Myeloma
An Open-label, Multicenter, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SHR-3836 in Patients With Multiple Myeloma
- Status
- Not Yet Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 99 (estimated)
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase I, open-label, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of SHR-3836 in patients with multiple myeloma (MM).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-3836 administered as multiple doses. | * In the dose escalation phase, doses are escalated sequentially from low to high levels. * In the dose expansion phase, one or more selected dose levels are further evaluated. |
Timeline
- Start date
- 2026-04-01
- Primary completion
- 2028-04-01
- Completion
- 2029-04-01
- First posted
- 2026-03-24
- Last updated
- 2026-03-24
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07490613. Inclusion in this directory is not an endorsement.